🏋️ “A slimdown in a syringe” — Weight Watchers’ Ozempic win. Rihanna’s perfume power. Tax Day’s big battle.

🏋️ “A slimdown in a syringe” — Weight Watche...

Nick & Jack StudiosNick & Jack Studios

Up next

🏝️ “Bread, shelter, caribbean” — Carnival’s sacrosanct cruises. Google’s space data center. Carnegie Mellon Miami’s $3B. +No-Phone-Zones

Carnival Cruises is setting record after record… because vacations are now sacrosanct.Google is launching a test data center on a SpaceX rocket… But will it work in space?Ken Griffin donated $3B to Carnegie Mellon University… To build a campus in Miami.$GOOG $CCL $SPCXGrab your T ...  Show more

 . 22min 10sec
⛷️ “Wipeout” — Vail’s ski recession. Anthropic’s IPO leak. Man City’s soccer sham. +Probiotic Undies

Vail Resorts reported a 12% drop in season pass sales… so they’re using a trick from baseball. Anthropic’s IPO paperwork leaked… it sells something worth $3 for just $1.Man City soccer is guilty of 115 fake deals worth £900M… They’re Performance Enhancing Deals.Plus, why apply sk ...  Show more

 . 21min 54sec

Recommended Episodes

The weight-loss drug revolution
Business Daily

Diabetes and obesity drugs like Ozempic, Wegovy and Mounjaro have become famous for helping users shed big amounts of weight. It's a market that could soon be worth more than $100 billion. Two companies dominate this space, Novo Nordisk which makes Ozempic and Eli Lilly, maker of ...  Show more

 . 17min 28sec
Encore: Diet Wars | Dieting 3.0 | 5
Business Wars

First there was Weight Watchers, then there was Noom, and now there’s…Wegovy? Bloomberg health reporter Emma Court helps us understand the evolution of dieting programs and where they’re going next. Later, Matthew Schnier of New York Magazine and The Cut walks us through his arti ...  Show more

 . 39min 12sec
How Many Points Is a Shot of Wegovy?
Listen to the Story

WeightWatchers is going all-in on trendy new anti-obesity drugs. The gamble might save the company—if it doesn’t kill it first. By Emma Court and Ellen HuetSee omnystudio.com/listener for privacy information. 

 . 27min 2sec
The obesity drug craze is entering its next phase
Viewsroom

Eli Lilly and Novo Nordisk can’t keep up with demand for their weight loss medications. In this Viewsroom podcast, Breakingviews columnists discuss the hype among celebrities, the different approaches to prescribing them in the US and Europe, and how they can reshape the world. V ...  Show more

 . 22min 46sec